“Endpoint Selection in Rare Disease Trials: Composite Measures and the Loss of Interpretability”. Translational Medicine & Therapeutics Journal 5, no. 2 (February 11, 2026): 10–18. Accessed November 5, 2026. https://inkwise.org/index.php/TMTJ/article/view/117.